Editorial: Clinical, Molecular and Adverse Responses to B-Cell Therapies in Autoimmune Disease.

Sciascia, Savino; Parodis, Ioannis; Karim, Mohammed Yousuf

Sciascia, Savino; Parodis, Ioannis; Karim, Mohammed Yousuf.

Sciascia S; University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont an
Parodis I; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Karim MY; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

Front Immunol ; 13: 962088, 2022.

Article in English | MEDLINE | ID: covidwho-1969023

Subject(s)

Autoimmune Diseases; Autoimmune Diseases/drug therapy; Humans; Rituximab/therapeutic use

Keywords

B-cell; adverse; allergy; autoimmunity; belimumab; hypogammaglobulinemia; neutropenia; rituximab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases Type of study: Prognostic study Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google